Rubius Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Public
  • Employees
  • 248
Employees
  • Stock Symbol
  • RUBY
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $19.30
  • (As of Thursday Closing)

Rubius Therapeutics General Information

Description

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 399 Binney Street
  • Suite 300
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Rubius Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.30 $19.31 $4.20 - $38.71 $1.73B 89.8M 363K -$2.09

Rubius Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,935,543 524,396 531,365 892,280
Revenue 0 0 0 0
EBITDA (163,684) (159,615) (165,867) (92,546)
Net Income (173,901) (167,731) (163,458) (89,195)
Total Assets 396,084 277,794 394,841 479,109
Total Debt 115,087 116,651 97,003 70,290
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rubius Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rubius Therapeutics‘s full profile, request access.

Request a free trial

Rubius Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Rubius Therapeutics‘s full profile, request access.

Request a free trial

Rubius Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer,
Drug Discovery
Cambridge, MA
248 As of 2021
00000
0.000 0000-00-00
00000000 00000

0000000

na aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Ecublens, Switzerland
00 As of 0000
00000
0000 00000

00000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
00000000000 0000000
Valencia, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rubius Therapeutics Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anokion Venture Capital-Backed Ecublens, Switzerland 00 00000 0000 00000
00000000 0000000 Venture Capital-Backed Valencia, CA 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 000 000.00 000000000 000.00
000000000 00000000 Venture Capital-Backed Newark, CA 0 000.00 000000 - 000 000.00
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
You’re viewing 5 of 17 competitors. Get the full list »

Rubius Therapeutics Executive Team (21)

Name Title Board Seat Contact Info
Pablo Cagnoni Ph.D Chief Executive Officer & Board Member
Jose Carmona Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Dannielle Appelhans Chief Operating Officer, Operations
Jordi Mata-Fink Ph.D Co-Founder, Director, Research & Director, Discovery
James Jogerst Chief Business Officer
You’re viewing 5 of 21 executive team members. Get the full list »

Rubius Therapeutics Board Members (15)

Name Representing Role Since
Anne Prener MD Self Board Member 000 0000
Catherine Sohn Self Board Member 000 0000
David Epstein Self Chairman & Board Member 000 0000
Francis Cuss Self Board Member 000 0000
Jonathan Symonds Ph.D Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Rubius Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rubius Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Rubius Therapeutics‘s full profile, request access.

Request a free trial

Rubius Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000,000-000000 000 25-Jul-2018 000000000 00000 00 Buildings and Property 00000 0000000 00.0
To view Rubius Therapeutics’s complete investments history, request access »